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By the end of June 2012 NOS News got hold of a concept
advice to the Minister of Health. It proposed to stop the
reimbursement of the orphan drugs Myozyme against
Pompe’s disease and Fabryzyme and Replagal against
Fabry’s disease. All three enzyme-therapies are very expen-
sive. The treatment for Pompe-patients costs roughly
between € 400.000 and € 700.000 a year, for Fabry-patients
about € 220.000 a year. The main argument for stopping
the compensation was the cost-ineffectiveness of the
enzyme-therapy. In other words: too much money for too
little result.
The concept advice was written by the CVZ, the main
advisor of the Minister on the health-insurance. The
Pompe and Fabry enzyme-therapies got insurance-cover-
age for a limited periode of four years beginning 2009.
The registration by the EMA was based on very limited
evidence.
The proposal to stop the reimbursement of Pompe and
Fabry therapies – only babies with the classical form of
Pompe would keep the compensation - , was the first ever
of this kind. There is no alternative treatment available.
And no patient can afford to pay hundreds of thousands
of euros year after year.
We realised that this proposal crossed a unique line.
Until 2012 CVZ refused the reimbursement of several
drugs. In the field of chronic diseases, for example, not
every new drug is automatically reimbursed. But there are
always alternatives that are. Not in this case.
We tried to publish this story with all parties concerned:
the patients and their organisations, the doctors specia-
lized in Pompe and Fabry diseases, the CVZ, the Health
Ministry. They all refused to comment. For five weeks we
tried to convince them, before we published without their
consent.
At first the messenger was blamed for the bad news. In
the end we were hailed for preventing this plan to become
reality. From July 2012 until October 2013 we closely fol-
lowed the decision making process. We attended hearings
where everybody had the opportunity to try to convince
the CVZ to change its views.
The CVZ refused to withdraw its proposal, but finally
made a U-turn and advised the Minister to maintain the
reimbursement of the therapies for all patients. The
patients and their relatives were relieved. One could argue
that common decency won.
But the real problem remains unsolved. Why are these
enzyme-therapies so expensive? Why are they so med-
iocre? Is it true that the industry lacks incentives to come
up with a better product since the limited one generates
such a substantial amount of money?
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